ArticleJournal of veterinary internal medicine2026
Association of impaired ammonia excretion with survival in dogs with stable chronic kidney disease.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIn people with chronic kidney disease (CKD), inadequate renal ammonia excretion contributes to metabolic acidosis and is associated with worse outcomes. However, the prognostic relevance of ammonia excretion in dogs with CKD remains unclear. HYPOTHESIS/
objectivesA reduced urine ammonia-to-creatinine ratio (UACR) would be associated with shorter survival and faster disease progression in dogs with stable CKD. ANIMALS: Fifty client-owned dogs with International Renal Interest Society (IRIS) stages II-IV CKD receiving a therapeutic renal diet.
methodsProspective, observational longitudinal study. Dogs were followed for up to 12 months or until death. Progressive CKD was defined as a > 25% increase in serum creatinine from baseline. Dogs were categorized based on UACR < 2.0 or ≥ 2.0. Associations with survival and CKD progression were assessed using Cox proportional hazards and Kaplan-Meier analyses.
resultsMost dogs were IRIS stage II (41/50, 82%). Dogs with UACR < 2.0 at enrollment had a significantly greater risk of death (HR 3.045; 95% CI, 1.372-7.102) and shorter median survival (189 vs 445 days, P = .008). Dogs with UACR < 2.0 also had a significantly shorter time to CKD progression (median 132 vs 445 days; P = .0002). In addition, UPC ratio < 1.0 was associated with a lower risk of death (HR 0.351; 95% CI, 0.142-0.879). CONCLUSIONS AND CLINICAL IMPORTANCE: Lower UACR (<2.0) was associated with higher case fatality and faster disease progression in dogs with azotemic CKD. Urine ammonia-to-creatinine ratio might be a useful biomarker for identifying dogs which could benefit from alkali therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.